The global Glandular Supplements Market was valued at USD 2.05 billion in 2023 and is projected to reach USD 4.38 billion by 2032, growing at a CAGR of 8.6% from 2024 to 2032. In 2022, the market stood at USD 1.89 billion, reflecting a 8.5% year-over-year (YoY) increase. Rising consumer awareness about organ health, along with an increase in functional and nutraceutical supplement adoption, is driving global demand.

Between 2018 and 2023, the Glandular Supplements Market expanded from USD 1.22 billion to USD 2.05 billion, reflecting cumulative growth of 68%. In 2019, revenue increased 7.9% YoY, followed by 8.2% in 2020 despite COVID-19 supply chain disruptions. Growth accelerated to 8.4% in 2021 and 8.5% in 2022 due to rising functional supplement usage and increased awareness of glandular therapy benefits.

By product type, adrenal gland supplements accounted for 34% of total revenue in 2023, generating USD 0.70 billion. Thyroid gland products contributed 27%, or USD 0.55 billion, while liver and kidney extracts combined for 21%, valued at USD 0.43 billion. Other glandular products, including pancreas and spleen extracts, represented 18%, generating USD 0.37 billion. Adrenal supplements exhibited a CAGR of 9.0% from 2020 to 2023.

Formulation-wise, capsules dominated with a 58% revenue share in 2023, valued at USD 1.19 billion. Powders accounted for 27%, or USD 0.55 billion, and liquid extracts represented 15%, generating USD 0.31 billion. Capsule-based supplements recorded a CAGR of 8.9% between 2020 and 2023 due to convenience, dosage accuracy, and rising e-commerce penetration.

Regionally, North America led the Glandular Supplements Market with a 37% share in 2023, generating USD 0.76 billion. The U.S. accounted for 91% of regional revenue. Europe held 28%, valued at USD 0.57 billion, with Germany, France, and the U.K. contributing 63% of European consumption. Asia-Pacific captured 25%, or USD 0.51 billion, and recorded the highest CAGR of 9.2% from 2018 to 2023.

Asia-Pacific revenue increased from USD 0.27 billion in 2018 to USD 0.51 billion in 2023, reflecting 88.9% growth over five years. China contributed 38% of regional revenue, India 25%, and Japan 21%. Government support for dietary supplements and increasing consumer spending on functional foods, totaling USD 1.3 billion in 2023, accelerated regional market adoption.

Historically, the Glandular Supplements Market showed steady expansion. From 2014 to 2018, revenue rose from USD 0.86 billion to USD 1.22 billion, reflecting a CAGR of 9.3%. Early growth was driven by the rise of natural health trends, increasing prevalence of thyroid and adrenal disorders, and availability of over-the-counter glandular formulations.

Survey data in 2023 indicated that 61% of consumers preferred glandular supplements derived from bovine sources, up from 48% in 2018. Approximately 58% of users reported using these supplements for adrenal support, while 42% cited thyroid health benefits. Retailers observed a 21% increase in sales of organ-specific formulations between 2021 and 2023.

Investment trends highlight growing market expansion. Global funding in nutraceutical and glandular supplement startups reached USD 142 million in 2022, up 18% from 2021. Mergers and acquisitions in the functional supplement sector totaled USD 310 million between 2020 and 2023. The top five global vendors accounted for 46% of total revenue in 2023.

Year-over-year comparisons demonstrate consistent growth. Revenue increased from USD 1.81 billion in 2021 to USD 1.89 billion in 2022, a 4.4% rise, followed by USD 2.05 billion in 2023, reflecting 8.5% YoY growth. Production volumes reached 12,650 metric tons in 2023, up from 11,340 tons in 2022, representing an 11.6% increase.

By end-user, direct-to-consumer sales contributed 61% of total revenue in 2023, valued at USD 1.25 billion, while hospitals and health clinics accounted for 23%, or USD 0.47 billion. Pharmacies represented 16%, generating USD 0.33 billion. Online sales recorded a 12% YoY increase in 2023 due to global e-commerce expansion and convenience-driven buying behavior.

Technological advancements are shaping the market. High-pressure extraction and freeze-drying techniques improved bioavailability by 18% from 2020 to 2023. AI-assisted quality control reduced product variation by 9%, while third-party testing for purity and potency became standard across 72% of manufacturers. These improvements strengthened consumer confidence and adoption.

Looking ahead, the Glandular Supplements Market is projected to exceed USD 2.88 billion by 2027. Adrenal and thyroid supplements are expected to grow at CAGRs of 9.1% and 8.7%, respectively, through 2032. North America is forecast to surpass USD 1.25 billion, Europe to reach USD 0.95 billion, and Asia-Pacific to exceed USD 0.80 billion by 2032.

Emerging markets in Latin America and the Middle East are projected to grow at CAGRs of 8.3% and 8.6%, respectively, driven by rising health awareness and increased functional food consumption. Government initiatives for dietary supplement regulation, totaling USD 235 million in 2023, further support market growth.

In conclusion, the Glandular Supplements Market is set to expand from USD 2.05 billion in 2023 to USD 4.38 billion by 2032, reflecting an 8.6% CAGR. With 12,650 metric tons of production, 58% capsule adoption, 61% direct-to-consumer revenue, and USD 142 million in nutraceutical investments, the market outlook is quantitatively strong. Rising consumer awareness, organ-specific formulations, and technological innovations will continue driving growth through 2032.

Read Full Research Study: https://marketintelo.com/report/glandular-supplements-market